DNA Biomed Financials

DNA Stock  ILS 76.90  0.20  0.26%   
Financial data analysis helps to check if markets are right now mispricing DNA Biomed Solns. We were able to analyze twenty-five available financial indicators for DNA Biomed, which can be compared to its peers in the sector. To ensure the equity is not overpriced, please confirm all DNA Biomed Solns financials, including its shares outstanding, cash and equivalents, beta, as well as the relationship between the price to book and cash flow from operations . The stock experiences a normal upward fluctuation. Check odds of DNA Biomed to be traded at S80.75 in 90 days.
With this module, you can analyze DNA financials for your investing period. You should be able to track the changes in DNA Biomed individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past DNA Biomed Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of DNA Biomed's financial statements are interrelated, with each one affecting the others. For example, an increase in DNA Biomed's assets may result in an increase in income on the income statement.
Evaluating DNA Biomed's financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of DNA Biomed's profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the DNA Biomed's relative financial performance

Chance Of Distress

Less than 37

 
100  
 
Zero
Below Average
DNA Biomed Solns has less than 37 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for DNA Biomed stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, DNA Biomed's odds of distress score SHOULD NOT be confused with the real chance of DNA Biomed Solns filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as DNA is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include DNA Biomed's liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in DNA Biomed's official financial statements usually reflect DNA Biomed's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of DNA Biomed Solns. For example, before you start analyzing numbers published by DNA accountants, it's critical to develop an understanding of what DNA Biomed's liquidity, profitability, and earnings quality are in the context of the Electronic Equipment, Instruments & Components space in which it operates.
Please note, the presentation of DNA Biomed's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DNA Biomed's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in DNA Biomed's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of DNA Biomed Solns. Please utilize our Beneish M Score to check the likelihood of DNA Biomed's management manipulating its earnings.

DNA Biomed Company Summary

DNA Biomed competes with Hiron Trade, Internet Gold, Isras Investment, and Arad Investment. D.N.A Biomedical Solutions Ltd. develops and commercializes laser spectrometry-based trace detection systems in Israel. D.N.A Biomedical Solutions Ltd. was founded in 2004 and is based in Ramat Gan, Israel. D N operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
Foreign Associate
  USA
InstrumentIsrael Stock View All
ExchangeTel Aviv Stock Exchange
ISINIL0011038523
Business AddressOz House, Petah
SectorElectronic Equipment, Instruments & Components
IndustryInformation Technology
BenchmarkNYSE Composite
Websitewww.laser-detect.com
Phone972 3 970 5000
CurrencyILS - Israeli Shekel
You should never invest in DNA Biomed without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of DNA Stock, because this is throwing your money away. Analyzing the key information contained in DNA Biomed's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

DNA Biomed Key Financial Ratios

Generally speaking, DNA Biomed's financial ratios allow both analysts and investors to convert raw data from DNA Biomed's financial statements into concise, actionable information that can be used to evaluate the performance of DNA Biomed over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that DNA Biomed Solns reports annually and quarterly.

DNA Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining DNA Biomed's current stock value. Our valuation model uses many indicators to compare DNA Biomed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DNA Biomed competition to find correlations between indicators driving DNA Biomed's intrinsic value. More Info.
DNA Biomed Solns is one of the top stocks in shares outstanding category among related companies. It is one of the top stocks in price to book category among related companies . The ratio of Shares Outstanding to Price To Book for DNA Biomed Solns is about  129,035,097 . Comparative valuation analysis is a catch-all model that can be used if you cannot value DNA Biomed by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for DNA Biomed's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DNA Biomed's earnings, one of the primary drivers of an investment's value.

DNA Biomed Solns Systematic Risk

DNA Biomed's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. DNA Biomed volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on DNA Biomed Solns correlated with the market. If Beta is less than 0 DNA Biomed generally moves in the opposite direction as compared to the market. If DNA Biomed Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one DNA Biomed Solns is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of DNA Biomed is generally in the same direction as the market. If Beta > 1 DNA Biomed moves generally in the same direction as, but more than the movement of the benchmark.

About DNA Biomed Financials

What exactly are DNA Biomed Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include DNA Biomed's income statement, its balance sheet, and the statement of cash flows. Potential DNA Biomed investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although DNA Biomed investors may use each financial statement separately, they are all related. The changes in DNA Biomed's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on DNA Biomed's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze DNA Biomed Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as DNA Biomed is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of DNA has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if DNA Biomed's financials are consistent with your investment objective using the following steps:
  • Review DNA Biomed's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand DNA Biomed's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare DNA Biomed's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if DNA Biomed's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

DNA Biomed March 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of DNA Biomed help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of DNA Biomed Solns. We use our internally-developed statistical techniques to arrive at the intrinsic value of DNA Biomed Solns based on widely used predictive technical indicators. In general, we focus on analyzing DNA Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build DNA Biomed's daily price indicators and compare them against related drivers.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DNA Biomed Solns. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
Note that the DNA Biomed Solns information on this page should be used as a complementary analysis to other DNA Biomed's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for DNA Stock analysis

When running DNA Biomed's price analysis, check to measure DNA Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNA Biomed is operating at the current time. Most of DNA Biomed's value examination focuses on studying past and present price action to predict the probability of DNA Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNA Biomed's price. Additionally, you may evaluate how the addition of DNA Biomed to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Please note, there is a significant difference between DNA Biomed's value and its price as these two are different measures arrived at by different means. Investors typically determine if DNA Biomed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DNA Biomed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.